Making Medicine

What if the next breakthrough medicine comes from China? Should American patients care where it was discovered? John Stanford and Max Bayer of @endpts examine the ethical questions surrounding proposed COINS Act restrictions. Check out the full episode on YouTube @MakingMedicinePod #COINSAct #ChinaBiotech #PatientAccess

Treasury's proposed COINS Act rules acknowledge potential risks to U.S. public health and American companies. What could that mean for biotech investment and patients? John Stanford and Max Bayer examine the implications on Making Medicine. Check out the full episode on YouTube @MakingMedicinePod #COINSAct #BiotechPolicy

Treasury says licensing isn't included in its proposed COINS Act rules. But what about biotech co-development and joint ventures? Max Bayer of @endpts joins John Stanford on Making Medicine to explain the uncertainty. Check out the full episode on YouTube @MakingMedicinePod #COINSAct #ChinaBiotech

Slowing China's biotech growth won't automatically strengthen America's. John Stanford argues that U.S. leadership depends on stronger research, venture investment, entrepreneurship, and FDA modernization. How should America compete? #AmericanBiotech #ChinaBiotech

Should it matter where a new medicine was first discovered? John Stanford examines how global biotech partnerships can support American drug development, and why restricting them may have consequences for patients. #Biotech #Innovation #Biotechnology @johnbstanford @MedicineMa80739 @incub8coalition @SMMT_TX

$120 billion in China biotech deals. But how much has actually been paid? John Stanford explains why licensing headlines can overstate actual cash flows—and what that means for U.S. biotech policy. #ChinaBiotech #BiotechInvestment #biotech #innovation #shorts youtu.be/0gtjKQjiLkE?si=L9Pr… via @YouTube @MakingMedPod @MedicineMa80739 @johnbstanford @incub8coalition @FiercePharma @FierceBiotech @FDA @NIH

💊Why are so many new medicines unavailable in Japan? @johnbstanford examines Japan's drug lag, pricing policies, and delayed pharmaceutical launches with @MNakada and @mjgutbrod. 🎙️Watch the episode on YouTube @MakingMedicinePod @JNJInnovation @incub8coalition @IAmBiotech @MedicineMa80739 #biotech #innovation #sh... youtu.be/dnoWhgDdkPY?si=3qrX… via @YouTube

Could Drug Price Controls Reduce Biotech Investment? What happens to biotech R&D when drug pricing rules change? Eddie Pauline explains why he believes government price-setting policies could affect future investment in pharmaceutical innovation. #biotech #innovation #ohio #mfn @incub8coalition @johnbstanford @cardinalhealth @LifeSciVC @MakingMedPod @MedicineMa80739 youtube.com/shorts/R62A1Fnbd… via @YouTube

“And we’re behind.” Eddie Pauline discusses China’s expanding biotech investment and clinical trial capabilities, and the opportunity to strengthen U.S. biotechnology through research hubs like Ohio. youtu.be/1K9tZSpMVwI?si=N0xE… via @YouTube #biotech #innovation #shorts @johnbstanford @incub8coalition @OSUWexMed @ClevelandClinic @JobsOhio @MedicineMa80739

Ohio Has 10% of America’s Gene Therapies? Ohio isn't just competing for biotech investment. It's building a gene therapy ecosystem. Eddie Pauline discusses Nationwide Children's role in roughly 10% of FDA-approved gene therapies and why biotech companies are taking notice. #biotech #innovation #shorts @OSUWexMed @NCHUrology @cardinalhealth @USGAO @LifeSciVC @NationwideKids @ClevelandClinic @JobsOhio @FDA @johnbstanford @incub8coalition @NIH @MakingMedPod @MedicineMa80739 youtu.be/ulF3t9HuURU?si=-mbT… via @YouTube

🧬 Biotech isn't just Boston and San Francisco anymore. Ohio Life Sciences CEO Eddie Pauline joins @johnbstanford to discuss Ohio's biotech growth, gene therapy, investment, drug pricing, and competition with China. 🎙️ Watch the new Making Medicine episode! #Biotech #LifeSciences @incub8coalition @OSUWexMed @NCHUrology @cardinalhealth @USGAO @LifeSciVC @nationwidekids @ClevelandClinic @JobsOhio @FDA @MakingMedPod @MedicineMa80739 Ohio’s Biotech Boom: Gene Therapy, Investment & the Race with China youtu.be/RsTFS-GNI-8?si=W9HY… via @YouTube

Can AI Really Deliver 100 Years of Biotech Progress in 10? #biotech #inn... youtu.be/nYYle-5Ng8Q?si=muic… via @YouTube “100 years of biotech in the next 10 years.” It's a powerful prediction about AI. Thomas Kaiser does the math, and argues that fulfilling it would require roughly 450–550 new drugs per year. Transformative technology? Absolutely. But extraordinary claims still need numbers behind them. #AI #Biotech #DrugDiscovery @johnbstanford @incub8coalition @FDA @NIH @DCVCBio @DCVC @AvicennaAi @MedicineMa80739

“Good Ideas Are Cheap”: The Reality of AI Drug Discovery #shorts #biotec... youtu.be/ngcdVgkjBWI?si=cTD2… via @YouTube “Good ideas are cheap. Durable ideas are the hard part.” That's Thomas Kaiser's reality check for AI in drug discovery. AI can dramatically expand what scientists can explore. But generating more ideas isn't the same as producing more successful medicines. #AIDrugDiscovery #Biotech #AI @incub8coalition @johnbstanford @FDA @NIH @AvicennaAi @DCVCBio @DCVC @MedicineMa80739

11 Compounds. 2 Drug Candidates. Is This AI’s Biotech Breakthrough? #sho... youtu.be/_VJ5-XjV42A?si=UX2N… via @YouTube Full Episode out NOW! #AIDrugDiscovery #Biotech #DrugDiscovery @incub8coalition @johnbstanford @DCVCBio @DCVC @MedicineMa80739

$12 billion. That's roughly a quarter of the venture capital invested in life sciences in 2025, committed to a single biotech acquisition. John Stanford explains what the Novartis/Avidity story reveals about the extraordinary risk behind drug development. Watch the full episode on YouTube @MakingMedicinePod #Biotech #Pharma #DrugDevelopment #LifeSciences

The cost of opening a Phase 1 clinical trial in the U.S. has doubled since 2017. Companies are opening fewer trials here and moving more research overseas. The bigger question: Could American patients stop being first in line for new breakthroughs? #ClinicalTrials #Biotech #DrugDevelopment Watch the full episode on YouTube @MakingMedicinePod

85% faced prior authorization. 40% had treatment delayed. Yet 95% of requests were eventually approved. John Stanford examines why FDA approval still doesn't guarantee patients timely access to a prescribed cancer treatment. Watch the full episode on YouTube @MakingMedicinePod #PatientAccess #PriorAuthorization #CancerCare #Biotech

Three clinical-stage assets. $400M raised. 50+ patients of clinical data within two years. Then a ~$2B upfront acquisition. Michael Rome explains how Candid Therapeutics came together, and what biotech VC can look like beyond writing a check. Watch the full discussion on the Making Medicine Podcast. Subscribe to the Making Medicine Podcast so you don't miss the next chapter of How America Makes Medicine our seven-part series celebrating 250 years of American pharmaceutical innovation. youtu.be/F2UH668b1zw?si=fFIP… #Biotech #VentureCapital #DrugDevelopment

🧬 What if we could build a vaccine not for a virus, but for one person's own cancer? Moderna and Merck's personalized mRNA cancer vaccine reached a major Phase 3 milestone. Here's why that matters. Watch the full discussion on the Making Medicine Podcast. Subscribe to the Making Medicine Podcast so you don't miss the next chapter of How America Makes Medicine our seven-part series celebrating 250 years of American pharmaceutical innovation. youtu.be/F2UH668b1zw?si=fFIP…

🇺🇸🧬China has a 25-year plan to become a global biotech leader. Dr. Jeremy Levin argues America can remain competitive, but we need to understand what it takes to compete. His football analogy: "One team is fully equipped. The other one doesn't have cleats, pads or helmets. Who's going to win?" Watch the full discussion on the Making Medicine Podcast. Subscribe to the Making Medicine Podcast so you don't miss the next chapter of How America Makes Medicine our seven-part series celebrating 250 years of American pharmaceutical innovation. #Biotech #AmericanInnovation #DrugDevelopment #HowAmericaMakesMedicine